|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients显示文摘AIM:To investigate whether the evaluation of tumor budding can complement K-RAS analysis to improve the individualized prediction of response to anti-epidermal growth factor receptor based therapies in metastatic colorectal cancer (mCRC) patients. METHODS:Forty-three patients with mCRC treated with cetuximab or panitumumab were entered into this study. According to the Response Evaluation Criteria in Solid Tumors criteria, 30 patients had stable or progressive disease (non-responsive), while 13 patients had a partial response. Tumor buds were evaluated from whole tissue sections stained for pan-cytokeratin, evaluated in the densest region using a 40 × objective and 'high-grade' tumor budding was defi ned as 15 buds/high-power f ield.RESULTS: Tumor buds and K-RAS mutation both correctly classif ied 68% of patients. All patients with K-RAS mutation (n=7) or high-grade tumor budding (n=11) were non-responsive, of which 4 patients had both features. All 13 partial responders were K-RAS wild-type with low-grade tumor budding. Combined, the predictive value of K-RAS and tumor budding was 80%. Additionally, high-grade tumor budding was significantly related to worse progression-free survival [HR (95% CI): 2.8 (1.3-6.0, P=0.008)].CONCLUSION: If confirmed in larger cohorts, the addition of tumor budding to K-RAS analysis may represent an effective approach for individualized patient management in the metastatic setting. | Inti Zlobec Francesca Molinari Vittoria Martin Luca Mazzucchelli Piercarlo Saletti Rosangela Trezzi Sara De Dosso Tatjana Vlajnic Milo Frattini Alessandro Lugli | 2010 | World Journal of Gastroenterology2010，16，38： | 4 |
| 2 | ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy显示文摘 | Sara Dosso Elena Zanellato Martina Nucifora Renzo Boldorini Angelica Sonzogni Roberto Biffi Nicola Fazio Eraldo Bucci Ottavio Beretta Stefano Crippa Piercarlo Saletti Milo Frattini | 2013 | Cancer Chemotherapy and Pharmacology2013，，1： | 2 |
| 3 | Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus显示文摘 | Di Nicolantonio Federica Arena Sabrina Tabernero Josep Grosso Stefano Molinari Francesca Macarulla Teresa Russo Mariangela Cancelliere Carlotta Zecchin Davide Mazzucchelli Luca Sasazuki Takehiko Shirasawa Senji Geuna Massimo Frattini Milo Ba | 2010 | Journal of Clinical Investigation2010，，8： | 1 |
| 4 | Aberrant promoter methylation of beta‐1,4 galactosyltransferase 1 as potential cancer‐specific biomarker of colorectal tumors显示文摘 | Maria Luana Poeta Emanuela Massi Paola Parrella Pasquale Pellegrini Mariangela De Robertis Massimiliano Copetti Carla Rabitti Giuseppe Perrone Andrea Onetti Muda Francesca Molinari Elena Zanellato Stefano Crippa Damiano Caputo Marco Caricato Milo Frattini | 2012 | Genes Chromosom Cancer2012，，12： | 1 |
| 5 | Research progress on KRAS mutations in colorectal cancer显示文摘The RAS gene family,responsible for signal transduction within the mitogen activated protein kinase(MAPK)and phosphatidylinositol 3 kinase(PI3K)pathways,is frequently involved in carcinogenesis,and alterations in its member genes can be detected,with variable frequency,in a wide variety of solid and hematological cancers.These alterations may behave as prognostic-predictive biomarkers and driver mutations,making them an interesting therapeutic target.Since their discovery,many strategies have been pursued to act on their signaling pathways.Indeed,in clinical practice,KRAS,the most prominent member of the RAS gene family,represents an especially elusive target in most malignancies;pathway inhibition is carried out upstream,on the EGFR receptor,or downstream,most frequently on the BRAF/MEK/ERK cascade.Recently,clinically relevant direct RAS inhibition has been successfully achieved with the development of potent and selective covalent inhibitors of KRAS c.34G>T(p.G12C).These latest-generation drugs represent both a new and interesting tool in the therapeutic armamentarium and a symbolic end to the myth of KRAS undruggability.However,their clinical relevance and appropriate place in treatment strategies remain to be determined. | Marco Cefalì Samantha Epistolio Maria Celeste Palmarocchi Milo Frattini Sara De Dosso | 2021 | Journal of Cancer Metastasis and Treatment2021，7，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员